The Food and Drug Administration (FDA) conditionally approved Varenzin-CA1 (molidustat oral suspension) for the control of nonregenerative anemia associated with chronic kidney disease (CKD) in cats. Nonregenerative anemia can be fatal because the cat’s bone marrow can’t produce enough red blood cells to replace the dead ones removed from the blood. This inhibits oxygen from being carried from the lungs throughout the body.
To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe to CatWatch
Get the next year of CatWatch for just $20. And access all of our back issues and online content free of charge.
Subscribe today and save 50% off the regular rate!
